RxDoctor Payments Data

Stephen Strategos, MD

Internal Medicine · Bakersfield, CANPI 1104856764

Payments from drug & device makers

$1,143in general payments, 2019–2025

Across 66 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$246
  • Astellas Pharma US Inc$155
  • Lilly USA, LLC$138
  • Kowa Pharmaceuticals America, Inc.$134
  • Amgen$89
  • AstraZeneca$71
  • plus $309 from 11 others

What the payments were for

  • Food & beverage$1,143100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,143 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$362,306
Medicare patients
505
Services billed
4,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide156$202,357
JardianceEmpagliflozin81$84,058
TrulicityDulaglutide52$64,890
FarxigaDapagliflozin Propanediol37$39,966
EliquisApixaban33$30,421
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$28,305
XareltoRivaroxaban28$25,368
MounjaroTirzepatide24$24,464
JanumetSitagliptin Phos/Metformin Hcl14$19,430
TradjentaLinagliptin24$17,774
MyrbetriqMirabegron14$14,264
SavellaMilnacipran Hcl17$13,610
RybelsusSemaglutide12$11,182
Repatha SureclickEvolocumab20$10,596
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$8,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$35$213,539168 claims
Lilly USA, LLCTrulicity, Mounjaro$138$89,35476 claims
AstraZenecaFarxiga$71$39,96637 claims
GSKTrelegy Ellipta, Anoro Ellipta$57$36,84050 claims
PfizerEliquis, Paxlovid$246$31,85044 claims
Johnson & JohnsonXarelto$23$25,36828 claims
MerckJanumet, Januvia$13$25,24325 claims
Astellas Pharma US IncMyrbetriq$155$14,26414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →